Author:
Berger Thomas,Elovaara Irina,Fredrikson Sten,McGuigan Chris,Moiola Lucia,Myhr Kjell-Morten,Oreja-Guevara Celia,Stoliarov Igor,Zettl Uwe K.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)
Reference100 articles.
1. Dayan C, Cuker A, LaGanke C, et al. Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis: 5-year follow-up of the CARE-MS studies. ECTRIMS meeting. 14–17 Sept 2016; London, UK: platform 168.
2. EMA. Lemtrada (alemtuzumab): EU summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf . Accessed Oct 2015.
3. US FDA. Lemtrada: prescribing information. 2016. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf . Accessed Oct 2015.
4. Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–70.
5. Turner MJ, Lamorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol. 2013;261(1–2):29–36.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献